COVID-19 Spike Protein (Omicron Variant) mRNA-LNP
The spike protein of COVID-19 is a glycoprotein that helps the virus attach to various surfaces in the built environment, increasing the potential for virus transmission. The best-known vaccines we use are the spike protein vaccines delivered via mRNA. While the role of vaccination in controlling outbreaks is undeniable, the recurring emergence of new variants of Covid-19, such as the Delta and Omicron variants, poses new challenges, particularly their rapid global spread. Since the end of 2021, Omicron has become the main COVID-19 variant that continues to affect human health. Multiple mutations in the Omicron spike protein, notably 15 mutations in its receptor-binding domain (RBD), allow the Omicron variant to evade neutralizing antibodies. This product is designed as a tool for the delivery and expression of full-length spike protein mRNA of COVID-19 Strain Omicron for vaccine research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of the Omicron spike protein mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The spike protein sequence of the Omicron (B.1.1.529) strain consists of 1270 amino acids, with multiple mutations compared to wild-type COVID-19. The GenPept accession number for the wild-type COVID-19 spike protein is UFO69279. The full-length amino acid sequence of this Spike mRNA-LNP product is available upon request.